Navigation Links
Regulus to Present at the Lazard Capital Markets Healthcare Conference
Date:11/8/2012

LA JOLLA, Calif., Nov. 8, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012 at 1:00 PM EST at the Pierre Hotel in New York City. 

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of the webcast will be archived on the Company's website for two weeks following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact

Amy Conrad
Director, Investor Relations and Corporate Communications
Regulus Therapeutics Inc.
858-202-6300
aconrad@regulusrx.com

Media

David Schull
Russo Partners LLC
212-845-4271
david.schull@russopartnersllc.com 


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
2. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
3. Regulus Files Registration Statement for Proposed Initial Public Offering
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Orlando, FL (PRWEB) , ... February 21, 2017 ... ... that enables healthcare organizations to build connected digital health applications, announced a partnership ... will enable users to seamlessly connect to many clinical systems while keeping data ...
(Date:2/21/2017)... Francisco, CA (PRWEB) , ... February 21, 2017 ... ... pleased to announce that Dr. Trevor Heritage has joined its executive team to ... revolutionary system designed to provide insights to help improve the diagnosis and treatment ...
(Date:2/21/2017)... ... 21, 2017 , ... VetStem Biopharma, Inc ., announced ... in Poway, California. Based upon 12 years of knowledge gained by following ... VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. This ...
(Date:2/21/2017)... LOS ANGELES , Feb. 21, 2017  Lexus, a returning ... its role as the official and exclusive automobile partner of the ... annual spring race. The 2017 Amgen Tour of ... five-year commitment and feature some of the best professional cycling teams ... , May 14-20. The four-day Amgen Breakaway from Heart ...
Breaking Biology Technology:
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
Breaking Biology News(10 mins):